Metabolic
Retatrutide
GGG triple agonist · LY3437943
Triple GIP / GLP-1 / glucagon receptor agonist — the next generation of incretin research.
5 mg10 mg15 mg20 mg30 mg +4
Retatrutide + Cagrilintide
Also known as: Triple agonist + amylin blend
Metabolic & GLP-1 Blend In stock Box of 10 vials 2 references
Triple-agonist and amylin analogue co-formulated 1:1.
Available sizes
| SKU | Per vial | Pack | |
|---|---|---|---|
| RC10 | 10 mg (5 + 5) | 10 vials / box |
Order Retatrutide + Cagrilintide
Pricing is quoted directly and is competitive at every tier — message us with the SKUs you want and quantities for a quote.
Replies within 36 hours. Cryptocurrency (preferred) or card / money-app with a processing fee. COA for this batch available on request.
A 1:1 co-formulation of retatrutide, the GIP/GLP-1/glucagon triple agonist 1, with the long-acting amylin analogue cagrilintide 2. Each component has independent phase 2 evidence; the blend is supplied for research into four-receptor pharmacology in a single preparation.
At a glance
- 5 mg retatrutide + 5 mg cagrilintide per vial
- Four receptor targets in one vial
Research use only. All products are sold strictly for laboratory research and development purposes. They are not intended for human or veterinary use, diagnosis, treatment, cure or prevention of any disease. Not for human consumption. Summaries above describe published findings in laboratory and clinical research models and do not constitute claims about this product.
- Form
- Lyophilized powder
- Purity
- HPLC-verified — Certificate of Analysis available on request
- Pack size
- Box of 10 vials
- Storage
- Lyophilized: −20 °C, protected from light (2–8 °C short-term). Reconstituted: 2–8 °C.
Sequence, formula and CAS data are provided for identification. Batch-specific purity, mass-spec and HPLC data are on the Certificate of Analysis — ask for it with your order.
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526.
- Lau DCW, Erichsen L, Francisco AM, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet. 2021;398(10317):2160-2172.
Citations retrieved from PubMed (NCBI). Links open the publisher record via DOI and the PubMed abstract.
Related
Often ordered together
Metabolic
Cagrilintide
Long-acting amylin analogue · NN9838
Once-weekly amylin analogue studied alone and in combination with semaglutide (CagriSema).
5 mg10 mg
Metabolic Blend
Cagrilintide + Semaglutide
CagriSema blend · Amylin + GLP-1 combination
Co-formulated amylin analogue and GLP-1 agonist in a single vial — the CagriSema research model.
5 mg (2.5 + 2.5)10 mg (5 + 5)